A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma.
Mark R. Albertini
Research Funding - Merck Serono
Erik Ranheim
No relevant relationships to disclose
Jacquelyn A Hank
No relevant relationships to disclose
Cindy Zuleger
No relevant relationships to disclose
Thomas McFarland
No relevant relationships to disclose
Jennifer Collins
No relevant relationships to disclose
Erin Clements
No relevant relationships to disclose
Sharon M. Weber
No relevant relationships to disclose
Tracey Weigel
No relevant relationships to disclose
Heather B. Neuman
No relevant relationships to disclose
Gregory K Hartig
No relevant relationships to disclose
David Mahvi
No relevant relationships to disclose
MaryBeth Henry
No relevant relationships to disclose
Jacek Gan
No relevant relationships to disclose
Richard Yang
No relevant relationships to disclose
KyungMann Kim
No relevant relationships to disclose
Stephen Gillies
No relevant relationships to disclose
Paul M. Sondel
No relevant relationships to disclose